Please login to the form below
ulcerative colitis
This page shows the latest ulcerative colitis news and features for those working in and with pharma, biotech and healthcare.
Gilead and Galapagos close in on filing for Xeljanz rival
RA and the rest from other diseases such as psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and atopic dermatitis.
Latest news
-
Celgene hopes for second time lucky for ozanimod FDA filing
Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, and is also being developed to treat ulcerative colitis and Crohn’s disease.Analysts had predicted the drug could reach peak
-
Takeda’s Entyvio tops Humira in ulcerative colitis
This landmark study raises the question of the optimal biologic for first-line therapy in patients with moderate to severely active ulcerative colitis.”. ... This is also the first time we have seen a direct comparison between two medicines with
-
Boehringer’s IL-36-targeting drug tackles rare form of psoriasis
Trials of BI 655130 are also underway in palmoplantar pustulosis (PPP), ulcerative colitis, Crohn’s disease and atopic dermatitis.
-
AbbVie and Boehringer’s psoriasis drug Skyrizi gets CHMP nod
Risankizumab is also being in clinical trials for a number of other inflammatory diseases, including Crohn's disease, ulcerative colitis, atopic dermatitis and psoriatic arthritis.
-
EMA could follow FDA’s Xeljanz blood clot warning
The higher dose of 10 mg twice a day is only approved for patients with ulcerative colitis.”. ... FDA. Xeljanz was approved for patients with ulcerative colitis in both the EU and US last year, but this group of patients wasn’t included in the safety
More from news
Approximately 20 fully matching, plus 105 partially matching documents found.
Latest Intelligence
-
Taking a lean and careful approach
ulcerative colitis, type 1 diabetes and inflammatory bowel disease.
-
Making digital health personal
Personalisation: A case study. This case study is of a digital health support programme that improved persistence of people with ulcerative colitis.
-
Deal Watch January 2017
Assembly Biosciences. Allergan. Exclusive global licence . 2 pc candidates for ulcerative colitis (ABI-M201) and Crohn's disease plus 2 compounds for IBS.
-
Forging a path in specialty care
Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA
-
Biosimilars - the same, but different?
The first months of 2015 also saw it approve Remsima and Inflectra for use on the NHS to treat moderately to severely active ulcerative colitis after the failure of conventional therapy.
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest appointments
-
Lorin Johnson joins Atlantic Healthcare board
Atlantic's lead asset, alicaforsen for the treatment of the inflammatory bowel diseases ulcerative colitis and pouchitis.
-
Ex J&J VP joins board of Immune
Its lead product candidate is bertilimumab, which is in clinical development for ulcerative colitis and Crohn's Disease as well as the rare skin condition bullous pemphigoid.
-
AstraZeneca veteran Deborah Hartman joins Avaxia
Will lead the development of AVX-470 in ulcerative colitis. Former AstraZeneca (AZ) vice president Dr Deborah Hartman has joined Avaxia Biologics as VP research, replacing Dan Tracey who retires. ... with active ulcerative colitis.
-
EMA’s Pharmacovigilance Risk Assessment Committee gains new members
Their respective alternates are Kirsten Myhr, from the Norwegian Board of Health, and Marco Greco, from the European Federation Crohn's and Ulcerative Colitis Associations.
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
emotive adds to medical team with new Scientific Lead and Associate Medical Writer
Kate is experienced in a wide range of therapy areas, including immunology, specifically Crohn’s disease, ulcerative colitis and psoriatic arthritis, in ophthalmology, including retinal diseases, glaucoma and dry eye disease,
-
Research Partnership has published a new Living with Ulcerative Colitis (UC) US market report for 2017
Living with Ulcerative Colitis (UC) is a study conducted amongst 110 adult UC patients in the US. ... The study employs a mixed quantitative/qualitative methodology and is available to purchase alongside our Living with Ulcerative Colitis 2016 5EU report.
-
Research Partnership launches new patient Living with Ulcerative Colitis (UC) US report
Living with Ulcerative Colitis (UC) is a study conducted amongst 100 adult UC patients in the US.
-
Lucid win PMEA Support Agency of the Year 2016
Highly Commended: Excellence in Healthcare Collaboration and Partnerships – The Ulcerative Colitis Endoscopic Index of Severity Online Tool . Jan Steele (Lucid Co-Founder andCOO) commented: “Being recognised for our work at these
-
Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016
Ulcerative Colitis (UC) is a progressive and debilitating disease which affects between 2.5 to 3 million people in Europe. Living with UC is a quantitative study conducted online amongst 325 ... patients, including both adult and paediatric patients
More from PMHub
Approximately 4 fully matching, plus 7 partially matching documents found.
Featured jobs
- Freelance Medical Writer - Healthcare Advertising - London
-
Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day
- Project Manager - Digital Healthcare - London
-
Excellent Remuneration Package
-
Director – Healthcare PR
-
Salary TBC
- Account Manager / Senior Account Manager - Healthcare Advertisin...
-
Excellent Remuneration
-
Account Director, Medical Education
-
Salary TBC
- Senior Account Director/ Associate Director- Pharma and Life Sci...
-
Competitive salary and benefits
- Account Director – London based Medical Communications Agency
-
Excellent Remuneration Package
- Project Manager - Medical Communications – South Wales
-
Excellent Remuneration Package
- Senior Account Manager- Pharma and Life Scienes
-
Competitive salary and benefits
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Senior Medical Writer
-
Salary TBC
- Senior / Principal Medical Writer - MedComms - Home Based / Vari...
-
Excellent Remuneration Packages
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Senior Medical Writer
-
Competitive salary and benefits
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Experienced / Senior Account Director - Publications - London
-
Up to £80, 000 plus great benefits
Subscribe to our email news alerts
- Hemlibra off to a flyer as Roche raises 2019 forecasts
- Stem cell transplant firms Kiadis and CytoSen join forces
- Gilead drives NASH development with insitro collaboration
- Red Consultancy expands healthcare team with three new hires
- Akcea steals march on Alnylam with NICE approval
- Catalent preps for complex therapy boom with $1.2bn Paragon buy
PMHub
Skills in Healthcare
At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...
Latest intelligence
- Cuttsy+Cuttsy awarded CPD Platinum by the IPA
- Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
- Breaking Bad
- Six behaviours separate the good brand teams from the bad...
- The first, my last, my everything
- The inescapable rise of patient-centricity...
Quick links
Infographics
